Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Innoviva, Inc. (INVA) - $25 value - yours FREE >>
Anavex Life Sciences Corp. (AVXL) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Innoviva, Inc. (INVA) - $25 value - yours FREE >>
Anavex Life Sciences Corp. (AVXL) - $25 value - yours FREE >>
Image: Bigstock
Kite (KITE) Enrolls ZUMA-1 Study, Interim Data, Filing in 2016
Kite Pharma, Inc. announced that it has finished enrolling patients in the diffuse large B-cell lymphoma (DLBCL) cohort of the phase II portion of the ZUMA-1 study on KTE-C19.
The company expects to report top-line data from the first 50 DLBCL patients in the ZUMA-1 study and also file for FDA approval, provided the results support the same, by year end. If all goes well, KTE-C19 could be launched as early as 2017. The company intends to file for EU approval in 2017.
KTE-C19, an anti-CD19 CAR-based therapy, is currently in three other pivotal studies as well. These include ZUMA-2 in patients with relapsed/refractory mantle cell lymphoma (MCL), ZUMA-3 for adult acute lymphoblastic leukemia (ALL) and ZUMA-4 for pediatric ALL, with results from all these studies due in 2017.
KTE-C19 has orphan drug status in the U.S. and EU for all the hematological indications being evaluated by the company - primary mediastinal B cell lymphoma (PMBCL), MCL, follicular lymphoma (FL), ALL, chronic lymphocytic leukemia (CLL) and DLBCL.
Moreover, last month, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) granted access to its newly established Priority Medicines (PRIME) regulatory initiative for KTE-C19 in the treatment of patients with refractory DLBCL. This status is granted to support the development and speed up the review of new therapies to treat patients with unmet medical need.
In the U.S., KTE-C19 has Breakthrough Therapy Designation for the treatment of patients with DLBCL, PMBCL, and transformed follicular lymphoma (TFL).
KITE PHARMA INC Price and Consensus
KITE PHARMA INC Price and Consensus | KITE PHARMA INC Quote
Kite is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the health care sector include Anavex Life Sciences Corp. (AVXL - Free Report) , Fibrocell Science, Inc. and Innoviva, Inc. (INVA - Free Report) – all three are Zacks Rank #1 (Strong Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>